ARCA biopharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ARCA biopharma generated cash of -$5,014,000, which is more than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore -$5,014,000.
Cash Flow
| 2014 | -9.40M | -19K | 8.02M |
|---|---|---|---|
| 2015 | -10.53M | -11K | 33.99M |
| 2016 | -14.98M | -16.41M | 0 |
| 2017 | -17.47M | 12.92M | 5.84M |
| 2018 | -8.24M | 3.04M | 3.10M |
| 2019 | -4.80M | -4K | 6.56M |
| 2020 | -7.72M | -19K | 48.45M |
| 2021 | -18.76M | -43K | 23.09M |
| 2022 | -10.91M | -2K | 0 |
| 2023 | -5.01M | 0 | 0 |
ABIO Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 42.44M | 53.35M | 49.07M | 8.36M | 6.60M | 8.70M | 7.40M | 38.80M | 15.35M | 16.75M |
Operating activities | ||||||||||
Net income | -5.33M | -9.92M | -19.32M | -9.73M | -5.48M | -7.93M | -18.49M | -16.44M | -11.44M | -9.68M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 111K | 114K | 91K | 93K | 89K | 22K | 356K | 320K | 19K | 12K |
Stock-based compensation expense | 686K | 556K | 497K | 43K | 151K | 0 | 458K | 576K | 599K | 647K |
| Deferred income tax benefit | 686K | 556K | 497K | 43K | 151K | 0 | 458K | 576K | 599K | 647K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 28K | -783K | -411K | 1.10M | 188K | -392K | -583K | 841K | -431K | 198K |
Cash generated by operating activities | -5.01M | -10.91M | -18.76M | -7.72M | -4.80M | -8.24M | -17.47M | -14.98M | -10.53M | -9.40M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | -5.47M | -20.50M | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -2K | -43K | -19K | -4K | -4K | -3K | -12K | -11K | -19K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | -2K | -43K | -19K | -4K | 3.04M | 12.92M | -16.41M | -11K | -19K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 24.07M | 50.89M | 7.28M | 3.53M | 6.55M | 0 | 37M | 9.03M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -408K | 0 | -311 | 0 | 0 | 0 | -179 |
Cash used in financing activities | 0 | 0 | 23.09M | 48.45M | 6.56M | 3.10M | 5.84M | 0 | 33.99M | 8.02M |
Net Change In Cash | -5.01M | -10.91M | 4.28M | 40.70M | 1.75M | -2.09M | 1.30M | -31.40M | 23.44M | -1.40M |
Cash at end of period | 37.43M | 42.44M | 53.35M | 49.07M | 8.36M | 6.60M | 8.70M | 7.40M | 38.80M | 15.35M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |